Evolent Health Inc Stock Price, News & Analysis

Evolent Health, Inc. (NYSE: EVH) will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 4:30 p.m. ET. CEO Seth Blackley and VP of Investor Relations Seth Frank will lead investor meetings and present at the event held in Boston, Massachusetts.

A live audio webcast will be accessible on Evolent's Investor Relations website.

Evolent Health provides clinical solutions aimed at improving health care delivery.

Evolent Health, Inc. (EVH) reported Q2 2022 revenue of $319.9 million, a 44.1% increase year-over-year. The net loss was $4.6 million, improving from a $9.1 million loss in Q2 2021. Adjusted EBITDA reached $21.7 million, reflecting a margin of 6.8%. The company added 10 new operating partnerships in 2022, exceeding its goal. Total Lives on Platform reached 21.9 million. For Q3, revenue guidance is set between $343.0 million and $363.0 million. Full-year revenue is projected to be $1.32 billion to $1.36 billion.

Evolent Health (NYSE: EVH) will report its second quarter 2022 operating results on August 2, 2022, post-market. A conference call is scheduled at 5:00 p.m. Eastern Time where interested parties can join by calling 855.940.9467 or 412.317.6034. An audio replay will be accessible on the company’s investor relations website for 90 days. Evolent Health is known for its clinical and administrative solutions aimed at improving health care affordability and efficiency, and serves a national client base among leading payers and providers.

Evolent Health has announced a definitive agreement to acquire IPG, a provider of surgical management solutions for musculoskeletal conditions, for $375 million plus up to $87 million in contingent consideration. The acquisition aims to enhance Evolent's position in value-based specialty care and is expected to be immediately accretive to Adjusted EBITDA margins and cash flow. The integration will diversify Evolent’s customer mix and provide valuable relationships with national commercial health plans.

Evolent Health, Inc. (NYSE: EVH) has announced that its CEO Seth Blackley, CFO John Johnson, and VP of Investor Relations Seth Frank will participate in several investor conferences in May and June 2022. The events include presentations at the BofA Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 17, and the 42nd Annual Growth Stock Conference on June 6. Additionally, Johnson and Frank will attend the J.P. Morgan Healthcare Services Summit on June 21, which will not be webcasted. Live webcasts will be available on the company's Investor Relations website.

Evolent Health, Inc. (NYSE: EVH) reported Q1 2022 revenues of $297.1 million, up 38.1% YoY, with net losses of $5.4 million. Adjusted EBITDA reached $24.3 million, yielding an 8.2% margin. Total lives on the platform stood at 20.3 million. The company announced new partnerships, including AvMed's expansion into oncology services and Bright Healthcare's member increase for 2023. For Q2 2022, revenue guidance is set at $290.0 million to $305.0 million, while full-year revenue is projected between $1.16 billion and $1.21 billion.

Evolent Health (NYSE: EVH) will announce its first quarter 2022 operating results on May 4, 2022, after the market closes. A conference call will follow at 5:00 p.m. Eastern Time. Interested shareholders can access the live broadcast by calling 855.940.9467 or 412.317.6034 (international). An audio playback will be available for 30 days on the company's investor relations website. Evolent Health provides clinical and administrative solutions to enhance healthcare delivery, serving a national network of leading payers and providers.

New Century Health (NCH) reported that its partner, Cancer Care Specialists (CCSI) of Illinois, earned nearly $3.6 million from Medicare through the Oncology Care Model (OCM). This payment reflects CCSI's success in reducing care costs while achieving quality targets for Medicare beneficiaries. Per-beneficiary costs were 8% below Medicare's benchmark, with high scores in patient experience and lower hospital utilization rates. NCH aims to improve patient outcomes and reduce expenses through effective oncology management and a focus on value-based care.